Sustainability in Preanalytics
Dr. Mads Nybo presents:
- Release Date: 01.04.2025
- Duration: 33 minutes
- Guest: Dr. Mads Nybo
- Host: Director Global Medical & Clinical Affairs Ana-Maria Å imundiÄ
- Introduction: Dr. Mads Nybo, chief physician at the Clinical Biochemistry department of the Odense University Hospital shares his views on and experience with sustainability in the medical sector.
Timestamps for Episode 3
- 01:33 - Sustainability is very much the word on the agenda
- 02:50 - Looking at Preanalytics from a sustainable point of view
- 04:53- The situation in Denmark
- 06:20- Finding a systematic approach
- 08:08- Laboratory solutions already in practice
- 10:45 - The demand management concept and low volume tubes
- 19:30 - Waste in laboratories
- 21:49 - Could blood collection tubes be circular?
What You Can't Miss – In a Nutshell
Stabilizing glucose has a great impact on diagnoses rates of diabetes
- Glucose declines rapidly in whole blood - at a rate of 7-8% per hour - so preventing this decline is important for accurate diagnosis of diabetes mellitus
Some stabilization methods are imperfect or impractical
- Sodium fluoride is a commonly used stabilizer, but whilst it inhibits enolase in the glycolytic pathway, other enzymes remain active and continue to metabolize glucose
Using a VACUETTEĀ® FC Mix tube does the job
- FC Mix tubes contain fluoride to inhibit enolase, citric acid to acidify the sample and inhibit other glycolytic enzymes, as well as EDTA that chelates the magnesium.
āAnd so stabilizing glucose to prevent its decline, has a great impact on those, the incidence of diabetes, diagnoses rates, so stabilizing glucose, to prevent its decline is quite important.ā
Get the latest from our podcast
Disclaimer & Shownotes
The guests interviewed in this podcast share their individual experiences with the use of our or comparable products and/or services. The opinions expressed are those of the interviewee and do not claim to represent the opinions or views of Greiner Bio-One. This information partially reflects the opinions of our customers and/or the experiences of individuals and does not claim to represent the opinions or views of Greiner Bio-One.
Products from Greiner Bio-One should only be used by appropriately trained medical professionals in accordance with the relevant instructions for use (IFU). A list of indications, contraindications, precautions, and warnings can be found in the instructions for use that accompany each product or can be downloaded from our website www.gbo.com (Download Center). For further information, please contact your local Greiner Bio-One distributor or visit our website.
All information is provided without guarantee despite careful processing. Liability, warranty, or guarantee of Greiner Bio-One GmbH is excluded. All rights, errors, and changes are reserved. Unless otherwise stated, Greiner Bio-One GmbH holds all copyrights and/or other (usage) rights in the present documents, especially to trademarks, such as the listed (word-image) marks, logos. Any use, reproduction, or other use of the rights of Greiner Bio-One GmbH is expressly prohibited.
Publisher and editor: Greiner Bio-One GmbH, Bad Haller Str. 32, 4550 KremsmĆ¼nster, Austria.
Mads Nybo mentioned this clinical trial conducted in 25 adult medical-surgical ICUs in Canada. The findings encouraged the Odense Hospital Team to reduce blood collection tube volumes.
Chapter 7.2.4.1 - General instructions on primary sample collection and handling include reviewing the sample volume requirements periodically to ensure that neither excessive nor insufficient amounts are collected.
